

### ERNEST D. BUFF & ASSOCIATES, LLC

RECEIVED CENTRAL FAX CENTER

SEP 2 2 2003

Intellectual Property Solutions

245 South Street Morristown, NJ 07960 (973) 644-0008 FAX (973) 644-4554

# FAX COVER SHEET

Date:

September 19, 2003

From:

Roger H. Criss

Client/Matter #:

0147-1

Re:

Serial No. 09/828,330, Filed April 6, 2001

Pages sent (including cover): 18

Examiner C. Nichols	USPTO - Art Unit 1647		703-872-9307	
RECIPIENT	FIRM	CC:	FAX NUMBER	

### Message:

Dear Dr. Nichols:

Enclosed for your information is a copy of the Amendment after Final Rejection that has been mailed today to the USPTO. The reason that the official copy is being mailed is because a check was required for the extension of time. However, I thought that you would like a copy at this time.

Should there be any questions, please let me know.

Respectfully submitted,

Roger H. Criss

Reg. No. 25,570

Enclosure

Confidentiality Note:

The documents accompanying this telecopy transmission contain information from the law firm of Ernest D. Buff & Associates, LLC, which is confidential and/or legally privileged. The information is intended only for the use of the individual or entity named in the transmittal sheets. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this telecopy is strictly prohibited. If you have received this telecopy in error, please immediately notify us by telephone so that we can arrange for the return of the original documents to us at no cost to you.

AMENDMENT TRANSMITTAL LETTER					ATTORNEY'S DOCKET NO.:			]
AND THE PROPERTY OF THE PROPER				0147-1 REC				
SERIAL NUMBER:		FILING	DATE:	EXAMIN	BR:	GROUP A		FAX CENTER
09/828,330		April	6, 2001	C. Nicl	hols	1647		
INVENTION:	מ אר אוים		CDAW	THE TRACTION OF	VACCUIT AD 1		SEP 2	2 2003
METHODS OF US GROWTH FACTO								
CHRONIC HEAR							A ALTIE	
								A B A B
inventor(s): Wayne l	P. France	<u> </u>						
TO THE ASSISTANT O				application. The fee	has been calculat	ed as shov	vn below.	20. 80. 3221
		CLA	IMSAS	AMENDED				
(1)		(2) CLAIMS	(3)	(4) HIGHEST NUMBER	(5) NO. OF EXTRA	(6) RATE	(7) ADDITION	
		REMAINING AFTER	l	PREVIOUSLY PAID FOR	CLAIMS PRESENT		AL FEE	
		AMENDMENT		TOR	T RESERVI			
TOTAL CLAIMS		24	MIN US	38	0	X \$9	0.00	
INDEP. CLAIMS	-	2	MIN US	5	0	X \$42	0.00	
•					AL ADDITIONAL R THIS AMENDMI		\$ 0.00	
TE II - antoni in andre	2 in law		a		C TIMO AND ADIA			
** If the "Highest Number."	Previously	s than the entry in co Paid For" IN THIS S	PACE is I	ess than 20, write "20"	in this space.			
*** If the 'Highest Number	ו		SPACE is	less than 3, write "3" i	n this space.			1
<b>'</b>	No addit required	tional fee is						
	i	•	to Do	anasit Ananunt				
	Charge \$		No.	posit Account			•	
<b>V</b>	The undi	ersigned petitions for	or any ex	tension of time for fil	ling this documen	t required	under 37	
				in the amount of \$55				
	Charge a	ny additional fees t	to Deposi	t Account No.				
		September 19, 20	03	R	in It Cris		ļ	
		Date			Signature			
				-	Roger H. Cri	SS		
		•	•		Attorney Name	,		
(973) 644-0008			-	25,570				
hereby certify that this co	nresnonde	Phone	v first els	we mail nostage area	Reg. Number	on A.F.		
Commissioner for Patents,						op Ar,		
				Roam	H Cris			
					(Signature)			
					Roger H. Cris	re		
				-	Attorney of Record	<u> </u>		
				c	September 19, 2	003		
					(Date)	-VUJ		
							•	

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Wayne D. Franco 09/828,330

Group Art Unit: Examiner:

1647 C. Nichols

Serial No.: Filed:

April 6, 2001

For:

METHODS OF USE OF FIBROBLAST GROWTH FACTOR, VASCULAR ENDOTHELIAL GROWTH FACTOR AND RELATED PROTEINS IN THE TREATMENT OF ACUTE

AND CHRONIC HEART DISEASE

Docket No.:

0147-1

Morristown, N.J. 07960 September 19, 2003

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

## **AMENDMENT AFTER FINAL REJECTION UNDER 37 CFR §1,116**

In response to the Final Rejection dated June 10, 2003, please amend the above-identified application as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 7 of this paper.